Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
NCT05385705 · Vall d'Hebron Institute of Oncology · PHASE1 · terminated · last registry update 2025-09-22 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow recruitment rate” | – | Registry record, Vall d'Hebron Institute of Oncology |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ERBB2 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-02Results posted on the registry: BeiGene, Zanidatamab + Docetaxel (NCT04276493)
- 2026-09-01Phase 3 first posted: Shanghai Jiao Tong University School of Medicine, Docetaxel + Pyrotinib (NCT07797218)
- 2026-08-20Also stopped (terminated): Jules Bordet Institute, Trastuzumab emtansine (NCT06595563)
- 2026-08-05Phase 3 first posted: Guangdong Provincial People's Hospital, THP×4 Q3W (n=296) (Investigator-selected taxane* + Trastuzumab IV 6 mg/kg, loading dose 8 mg/kg + Pertuzumab IV 420 mg, loading dose 840mg) + THP×6 Q3W (n=296) (Investigator-selected taxane* + Trastuzumab IV 6 mg/kg, loading dose 8 mg/kg + Pertuzumab IV 420 mg, loading dose 840mg) (NCT07748260)
- 2026-07-24Results posted on the registry: Memorial Sloan Kettering Cancer Center, Gemcitabine + Trastuzumab (NCT02252887)
- 2026-07-06Phase 3 first posted: Daiichi Sankyo, Trastuzumab deruxtecan + Trastuzumab (NCT07683754)
- 2026-06-29Phase 3 first posted: GeneQuantum Healthcare (Suzhou) Co., Ltd., GQ1005 + T-DM1 (NCT07673029)
- 2026-06-09Results posted on the registry: AstraZeneca, Trastuzumab Deruxtecan + Paclitaxel (NCT05113251)
- 2026-05-29Also stopped (terminated): National Cancer Institute (NCI), Atezolizumab + Docetaxel (NCT03199885)
- 2026-05-11Phase 3 first posted: SWOG Cancer Research Network, Cyclin-Dependent Kinase 4 Inhibitor + Cyclin-Dependent Kinase 6 Inhibitor (NCT07578116)
- 2026-04-29Results posted on the registry: Dana-Farber Cancer Institute, T-DM1 (NCT03587740)
- 2026-04-21Also stopped (terminated): Institut Paoli-Calmettes, BKM120 + lapatinib (NCT01589861)
- 2026-04-20Results posted on the registry: The Methodist Hospital Research Institute, Durvalumab + Trastuzumab (NCT03820141)
- 2026-04-08Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-M07D1 + Pertuzumab (NCT07518173)
- 2026-04-02Also stopped (terminated): Spanish Breast Cancer Research Group, Trastuzumab deruxtecan (NCT05744375)
- 2026-03-13Also stopped (terminated): Biocon Biologics UK Ltd, PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxel (NCT06038539)
- 2026-03-12Results posted on the registry: Spanish Breast Cancer Research Group, Trastuzumab deruxtecan (NCT05744375)
- 2026-03-02Phase 3 first posted: Shanghai JMT-Bio Inc., KN026 + HB1801 (NCT07441460)
- 2026-02-17Phase 3 first posted: Hoffmann-La Roche, RO7771950 + Tucatinib (NCT07413939)
- 2026-02-12Results posted on the registry: Alliance Foundation Trials, LLC., palbociclib + trastuzumab (NCT02947685)
- 2026-02-12Results posted on the registry: M.D. Anderson Cancer Center, Cyclophosphamide + Doxorubicin (NCT03101748)
- 2026-02-12Also stopped (terminated): M.D. Anderson Cancer Center, Cyclophosphamide + Doxorubicin (NCT03101748)
- 2026-02-04Phase 3 first posted: R-Pharm, RPH-051 + Docetaxel (NCT07386938)
- 2026-01-30Phase 3 first posted: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD., Trastuzumab + IBI354 (NCT07377643)
- 2026-01-22Also stopped (terminated): Dana-Farber Cancer Institute, Neratinib + Fulvestrant (NCT03289039)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision